申请人:——
公开号:US20020151555A1
公开(公告)日:2002-10-17
Selective MMP-13 inhibitors are pyrimidine derivatives of the formula
1
or a pharmaceutically acceptable salt thereof,
wherein:
R
2
is hydrogen, halo, hydroxy, C
1
-C
6
alkyl, C
1
-C
6
alkoxy, C
2
-C
6
alkenyl, C
2
-C
6
alkynyl, NO
2
, NR
4
R
5
, CN, or CF
3
;
E is independently O or S;
A and B independently are OR
4
or NR
4
R
5
; R
4
and R
5
independently are H, C
1
-C
6
alkyl, C
2
-C
6
alkenyl, C
2
-C
6
alkynyl, (CH
2
)
n
aryl, (CH
2
)
n
cycloalkyl, (CH
2
)n heteroaryl, or R
4
and R
5
when taken together with the nitrogen to which they are attached complete a 3- to 8-membered ring containing carbon atoms and optionally containing a heteroatom selected from O, S, or NH, and optionally substituted or unsubstituted;
n is an integer of from 0 to 6.
选择性MMP-13抑制剂是式1的嘧啶衍生物或其药学上可接受的盐,其中:
R2是氢、卤素、羟基、C1-C6烷基、C1-C6烷氧基、C2-C6烯基、C2-C6炔基、NO2、NR4R5、CN或CF3;
E独立地为O或S;
A和B独立地为OR4或NR4R5;
R4和R5独立地为H、C1-C6烷基、C2-C6烯基、C2-C6炔基、(CH2)n芳基、(CH2)n环烷基、(CH2)n杂环芳基,或者R4和R5在一起与它们所连接的氮形成一个含有碳原子并且可选地含有O、S或NH等杂原子的3-8元环,且可选地被取代或未取代;
n为0至6的整数。